Didehydro-cortistatin a inhibits HIV-1 tat mediated neuroinflammation and prevents potentiation of cocaine reward in tat transgenic mice

Current HIV Research

Volumn 13, Issue 1, 2015, Pages 64-79

  Mediouni, Sonia ^a   Jablonski, Joseph ^a   Paris, Jason J ^b   Clementz, Mark A ^a   Thenin Houssier, Suzie ^a   McLaughlin, Jay P ^b   Valente, Susana T ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

Cocaine; Conditioned place preference; Didehydro Cortistatin A; HAND; HIV 1; Neuroinflammation; Reward; Tat

Indexed keywords

CHEMOKINE; COCAINE; CORTISTATIN; CYTOKINE; DIDEHYDRO CORTISTATIN A; DOXYCYCLINE; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RALTEGRAVIR; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDEHYDRO-CORTISTATIN A; DOPAMINE UPTAKE INHIBITOR; FUSED HETEROCYCLIC RINGS; ISOQUINOLINE DERIVATIVE;

ADULT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BEHAVIOR ASSESSMENT; BLOOD BRAIN BARRIER; CELL VIABILITY; CONTROLLED STUDY; DRUG PENETRATION; EC50; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HIV ASSOCIATED DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOFLUORESCENCE TEST; LIQUID CHROMATOGRAPHY; LUCIFERASE ASSAY; MALE; MASS SPECTROMETRY; MOUSE; MTT ASSAY; NERVE CELL LESION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSACTIVATION ASSAY; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; HIV INFECTIONS; INFLAMMATION; METABOLISM; NEUROCOGNITIVE DISORDERS; PHYSIOLOGY; REWARD; TRANSGENIC MOUSE;

ANIMALS; ANTI-HIV AGENTS; CHEMOKINES; COCAINE; CYTOKINES; DISEASE MODELS, ANIMAL; DOPAMINE UPTAKE INHIBITORS; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HIV INFECTIONS; HIV-1; INFLAMMATION; ISOQUINOLINES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROCOGNITIVE DISORDERS; REWARD; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84928723998     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X13666150121111548     Document Type: Article

References (95)

1. [1] Kaul M. HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches. Curr Opin Neurol. 2009;22(3):315-20.
2. [2] Kaul M, Zheng J, Okamoto S, et al. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ. 2005;12 Suppl 1:878-92.
3. [3] Bagashev A, Sawaya BE. Roles and functions of HIV-1 Tat protein in the CNS: an overview. Virol J. 2013;10:358.
4. [4] Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5(1):69-81.
5. [5] Gorry PR, Howard JL, Churchill MJ, et al. Diminished production of human immunodeficiency virus type 1 in astrocytes results from inefficient translation of gag, env, and nef mRNAs despite efficient expression of Tat and Rev. J Virol. 1999;73(1):352-61.
6. [6] Gorry PR, Ong C, Thorpe J, et al. Astrocyte infection by HIV-1: mechanisms of restricted virus replication, and role in the pathogenesis of HIV-1-associated dementia. Curr HIV Res. 2003;1(4):463-73.
7. [7] Kleinschmidt A, Neumann M, Moller C, et al. Restricted expression of HIV1 in human astrocytes: molecular basis for viral persistence in the CNS. Res Virol. 1994;145(3-4):147-53.
8. [8] Chan P, Brew BJ. HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. Curr HIV/AIDS Rep. 2014;11(3):317-24.
9. [9] Heaton RK, Clifford DB, Franklin DR, Jr., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087-96.
10. [10] Campbell GR, Loret EP. What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? Retrovirology. 2009;6:50.
11. [11] Mousseau G, Valente S. Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors. Biology (Basel). 2012;1(3):668-97.
12. [12] King JE, Eugenin EA, Buckner CM, et al. HIV tat and neurotoxicity. Microbes Infect. 2006;8(5):1347-57.
13. [13] Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 1988;55(6):1189-93.
14. [14] Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A. 1994;91(2):664-8.
15. [15] Debaisieux S, Rayne F, Yezid H, et al. The ins and outs of HIV-1 Tat. Traffic. 2012;13(3):355-63.
16. [16] Chang HC, Samaniego F, Nair BC, et al. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS. 1997;11(12):1421-31.
17. [17] Ensoli B, Buonaguro L, Barillari G, et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol. 1993;67(1):277-87.
18. [18] Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis. 2002;186 Suppl 2:S193-8.
19. [19] Ma M, Nath A. Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. J Virol. 1997;71(3):2495-9.
20. [20] Maletinska L, Blakely EA, Bjornstad KA, et al. Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res. 2000;60(8):2300-3.
21. [21] Eugenin EA, King JE, Nath A, et al. HIV-tat induces formation of an LRP-PSD-95-NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. Proc Natl Acad Sci U S A. 2007;104(9):3438-43.
22. [22] Liu Y, Jones M, Hingtgen CM, et al. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med. 2000;6(12):1380-7.
23. [23] Albini A, Soldi R, Giunciuglio D, et al. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med. 1996;2(12):1371-5.
24. [24] Albini A, Ferrini S, Benelli R, et al. HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci U S A. 1998;95(22):13153-8.
25. [25] Nath A, Conant K, Chen P, et al. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem. 1999;274(24):17098-102.
26. [26] Zhao L, Pu SS, Gao WH, et al. Effects of HIV-1 tat on secretion of TNF-alpha and IL-1beta by U87 cells in AIDS patients with or without AIDS dementia complex. Biomed Environ Sci. 2014;27(2):111-7.
27. [27] Chen X, Liu W, Ambrosino C, et al. Impaired generation of bone marrow B lymphocytes in mice deficient in C/EBPbeta. Blood. 1997;90(1):156-64.
28. [28] Chauhan A, Turchan J, Pocernich C, et al. Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J Biol Chem. 2003;278(15):13512-9.
29. [29] Lee EO, Kim SE, Park HK, et al. Extracellular HIV-1 Tat upregulates TNF-alpha dependent MCP-1/CCL2 production via activation of ERK1/2 pathway in rat hippocampal slice cultures: inhibition by resveratrol, a polyphenolic phytostilbene. Exp Neurol. 2011;229(2):399-408.
30. [30] Kim SE, Lee EO, Yang JH, et al. 15-deoxy-Delta(1)(2),(1)(4)-prostaglandin J(2) inhibits human immunodeficiency virus-1 tatinduced monocyte chemoattractant protein-1/CCL2 production by blocking the extracellular signal-regulated kinase-1/2 signaling pathway independently of peroxisome proliferator-activated receptor-gamma and heme oxygenase-1 in rat hippocampal slices. J Neurosci Res. 2012;90(9):1732-42.
31. [31] Sawaya BE, Thatikunta P, Denisova L, et al. Regulation of TNFalpha and TGFbeta-1 gene transcription by HIV-1 Tat in CNS cells. J Neuroimmunol. 1998;87(1-2):33-42.
32. [32] Conant K, Garzino-Demo A, Nath A, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A. 1998;95(6):3117-21.
33. [33] Gallo P, Frei K, Rordorf C, et al. Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system: an evaluation of cytokines in cerebrospinal fluid. J Neuroimmunol. 1989;23(2):109-16.
34. [34] Brabers NA, Nottet HS. Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. Eur J Clin Invest. 2006;36(7):447-58.
35. [35] Merrill JE, Koyanagi Y, Chen IS. Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol. 1989;63(10):4404-8.
36. [36] Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 2000;23(12):618-25.
37. [37] Griffin BD, Moynagh PN. Persistent interleukin-1beta signaling causes long term activation of NFkappaB in a promoter-specific manner in human glial cells. J Biol Chem. 2006;281(15):10316-26.
38. [38] Ambrosino C, Ruocco MR, Chen X, et al. HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. J Biol Chem. 1997;272(23):14883-92.
39. [39] Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005;5(8):629-40.
40. [40] Moynagh PN. The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain. J Anat. 2005;207(3):265-9.
41. [41] Vitkovic L, Chatham JJ, da Cunha A. Distinct expressions of three cytokines by IL-1-stimulated astrocytes in vitro and in AIDS brain. Brain Behav Immun. 1995;9(4):378-88.
42. [42] Li W, Li G, Steiner J, et al. Role of Tat protein in HIV neuropathogenesis. Neurotox Res. 2009;16(3):205-20.
43. [43] Kelder W, McArthur JC, Nance-Sproson T, et al. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol. 1998;44(5):831-5.
44. [44] Madrigal JL, Leza JC, Polak P, et al. Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J Neurosci. 2009;29(1):263-7.
45. [45] Eugenin EA, D'Aversa TG, Lopez L, et al. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem. 2003;85(5):1299-311.
46. [46] Gonzalez E, Rovin BH, Sen L, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A. 2002;99(21):13795-800.
47. [47] Chinta SJ, Andersen JK. Dopaminergic neurons. Int J Biochem Cell Biol. 2005;37(5):942-6.
48. [48] Maragos WF, Young KL, Turchan JT, et al. Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J Neurochem. 2002;83(4):955-63.
49. [49] Yao H, Buch S. Rodent models of HAND and drug abuse: exogenous administration of viral protein(s) and cocaine. J Neuroimmune Pharmacol. 2012;7(2):341-51.
50. [50] Ferris MJ, Frederick-Duus D, Fadel J, et al. The human immunodeficiency virus-1-associated protein, Tat1-86, impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study. Neuroscience. 2009;159(4):1292-9.
51. [51] Ferris MJ, Frederick-Duus D, Fadel J, et al. In vivo microdialysis in awake, freely moving rats demonstrates HIV-1 Tat-induced alterations in dopamine transmission. Synapse. 2009;63(3):181-5.
52. [52] Wallace DR. HIV neurotoxicity: potential therapeutic interventions. J Biomed Biotechnol. 2006;2006(3):65741.
53. [53] Zhu J, Ananthan S, Mactutus CF, et al. Recombinant human immunodeficiency virus-1 transactivator of transcription1-86 allosterically modulates dopamine transporter activity. Synapse. 2011;65(11):1251-4.
54. [54] Nath A, Anderson C, Jones M, et al. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol. 2000;14(3):222-7.
55. [55] Kousik SM, Napier TC, Carvey PM. The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation. Front Pharmacol. 2012;3:121.
56. [56] Kim BO, Liu Y, Ruan Y, et al. Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol. 2003;162(5):1693-707.
57. [57] Paris JJ, Carey AN, Shay CF, et al. Effects of Conditional Central Expression of HIV-1 Tat Protein to Potentiate Cocaine-Mediated Psychostimulation and Reward Among Male Mice. Neuropsychopharmacology. 2014;39(2):380-8.
58. [58] Mousseau G, Clementz MA, Bakeman WN, et al. An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tatdependent HIV transcription. Cell Host Microbe. 2012;12(1):97-108.
59. [59] Pierleoni R, Menotta M, Antonelli A, et al. Effect of the redox state on HIV-1 tat protein multimerization and cell internalization and trafficking. Mol Cell Biochem. 2010;345(1-2):105-18.
60. [60] Mediouni S, Baillat G, Darque A, et al. HIV-1 infected patients have antibodies recognizing folded Tat. Infect Disord Drug Targets. 2011;11(1):57-63.
61. [61] Chanput W, Mes J, Vreeburg RA, et al. Transcription profiles of LPS-stimulated THP-1 monocytes and macrophages: a tool to study inflammation modulating effects of food-derived compounds. Food Funct. 2010;1(3):254-61.
62. [62] Carey AN, Liu X, Mintzopoulos D, et al. Conditional Tat protein expression in the GT-tg bigenic mouse brain induces gray matter density reductions. Prog Neuropsychopharmacol Biol Psychiatry. 2013;43:49-54.
63. [63] Paris JJ, Singh HD, Ganno ML, et al. Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat. Psychopharmacology (Berl). 2014;231(11):2349-60.
64. [64] McCormack ES, Borzillo GV, Ambrosino C, et al. Transforming growth factor-beta3 protection of epithelial cells from cycleselective chemotherapy in vitro. Biochem Pharmacol. 1997;53(8):1149-59.
65. [65] Eans SO, Ganno ML, Reilley KJ, et al. The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting kappa opioid receptor antagonism in the CNS after oral administration. Br J Pharmacol. 2013;169(2):426-36.
66. [66] Carey AN, Borozny K, Aldrich JV, et al. Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn. Eur J Pharmacol. 2007;569(1-2):84-9.
67. [67] McLaughlin JP, Land BB, Li S, et al. Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology. 2006;31(4):787-94.
68. [68] Hemelaar J, Gouws E, Ghys PD, et al. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS. 2011;25(5):679-89.
69. [69] Banks WA, Robinson SM, Nath A. Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol. 2005;193(1):218-27.
70. [70] Westendorp MO, Shatrov VA, Schulze-Osthoff K, et al. HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J. 1995;14(3):546-54.
71. [71] Xiao H, Neuveut C, Tiffany HL, et al. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci U S A. 2000;97(21):11466-71.
72. [72] Vitkovic L, da Cunha A. Role for astrocytosis in HIV-1-associated dementia. Curr Top Microbiol Immunol. 1995;202:105-16.
73. [73] Ridet JL, Malhotra SK, Privat A, et al. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 1997;20(12):570-7.
74. [74] Tatro ET, Soontornniyomkij B, Letendre SL, et al. Cytokine secretion from brain macrophages infected with human immunodeficiency virus in vitro and treated with raltegravir. BMC Infect Dis. 2014;14:386.
75. [75] Zhang X, Cao R, Liu R, et al. Reduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages. PLoS One. 2014;9(3):e90856.
76. [76] Hauber J, Perkins A, Heimer EP, et al. Trans-activation of human immunodeficiency virus gene expression is mediated by nuclear events. Proc Natl Acad Sci U S A. 1987;84(18):6364-8.
77. [77] Siomi H, Shida H, Maki M, et al. Effects of a highly basic region of human immunodeficiency virus Tat protein on nucleolar localization. J Virol. 1990;64(4):1803-7.
78. [78] Weeks BS, Lieberman DM, Johnson B, et al. Neurotoxicity of the human immunodeficiency virus type 1 tat transactivator to PC12 cells requires the Tat amino acid 49-58 basic domain. J Neurosci Res. 1995;42(1):34-40.
79. [79] Buonaguro L, Tornesello ML, Buonaguro FM. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol. 2007;81(19):10209-19.
80. [80] Zhang X, Zhang X, Wang F. Intracellular transduction and potential of Tat PTD and its analogs: from basic drug delivery mechanism to application. Expert Opin Drug Deliv. 2012;9(4):457-72.
81. [81] Snyder EL, Dowdy SF. Protein/peptide transduction domains: potential to deliver large DNA molecules into cells. Curr Opin Mol Ther. 2001;3(2):147-52.
82. [82] Hui B, Geng MY, Li J. [Effect of sulfated polymannuroguluronate on Tat induced proinflammatory cytokines release in THP-1 cells and its mechanism of action]. Yao Xue Xue Bao. 2006;41(4):338-41.
83. [83] Gerbi SA, Borovjagin AV, Lange TS. The nucleolus: a site of ribonucleoprotein maturation. Curr Opin Cell Biol. 2003;15(3):318-25.
84. [84] Galati D, Paiardini M, Cervasi B, et al. Specific changes in the posttranslational regulation of nucleolin in lymphocytes from patients infected with human immunodeficiency virus. J Infect Dis. 2003;188(10):1483-91.
85. [85] Michienzi A, Cagnon L, Bahner I, et al. Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA. Proc Natl Acad Sci U S A. 2000;97(16):8955-60.
86. [86] Michienzi A, Li S, Zaia JA, et al. A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A. 2002;99(22):14047-52.
87. [87] Jarboui MA, Bidoia C, Woods E, et al. Nucleolar protein trafficking in response to HIV-1 Tat: rewiring the nucleolus. PLoS One. 2012;7(11):e48702.
88. [88] Zhang R, Bloch N, Nguyen LA, et al. SAMHD1 restricts HIV-1 replication and regulates interferon production in mouse myeloid cells. PLoS One. 2014;9(2):e89558.
89. [89] Song JH, Bellail A, Tse MC, et al. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J Neurosci. 2006;26(12):3299-308.
90. [90] Lee JM, Calkins MJ, Chan K, et al. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem. 2003;278(14):12029-38.
91. [91] Kim SG, Gao ZG, Soltysiak KA, et al. P2Y6 nucleotide receptor activates PKC to protect 1321N1 astrocytoma cells against tumor necrosis factor-induced apoptosis. Cell Mol Neurobiol. 2003;23(3):401-18.
92. [92] Choi SS, Lee HJ, Lim I, et al. Human astrocytes: secretome profiles of cytokines and chemokines. PLoS One. 2014;9(4):e92325.
93. [93] Larson SJ, Dunn AJ. Behavioral effects of cytokines. Brain Behav Immun. 2001;15(4):371-87.
94. [94] Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci. 2002;25(3):154-9.
95. [95] Marker DF, Tremblay ME, Puccini JM, et al. The new smallmolecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders. J Neurosci. 2013;33(24):9998-10010